Alkermes Plc(NASDAQ) ALKS

Alkermes plc treats people with brain and nervous system disorders. These treatments help patients manage schizophrenia, addiction, and sleep conditions. The company sells these specialty drugs to pharmacies across the country.

Medicines for the Mind

• VIVITROL: Injectable medication for alcohol dependence and preventing opioid relapse; used once every four weeks.
• ARISTADA: Long-acting injectable treatment for adults with schizophrenia; utilizes proprietary technology for extended release.
• LYBALVI: Daily oral tablet for schizophrenia and bipolar I disorder; combines an antipsychotic with an opioid antagonist.
• LUMRYZ: Once-at-bedtime oral liquid for cataplexy or daytime sleepiness in narcolepsy patients.
• Licensed Products: Royalty-generating portfolio including multiple sclerosis and schizophrenia treatments marketed by partners like Biogen and Janssen.

Strategic Acquisitions and Trials

• Acquired Avadel Pharmaceuticals on Feb. 12, 2026, to add LUMRYZ to its proprietary lineup.
• Initiated Phase 3 studies in April 2026 for the sleep disorder treatment alixorexton.
• Borrowed $1.5 billion in February 2026 to finance its acquisition and operations.
• Reported positive results from its REVITALYZ Phase 3 study in May 2026.

How Does the Technology Work?

Alkermes uses proprietary platforms like LINKERX and NANOCRYSTAL to create long-acting versions of existing medications. These technologies help deliver precise levels of medicine in the body over several weeks or months.

By the Numbers

• Total revenue increased $105.4 million in the three months ended June 30, 2026, compared to the same period in 2025.
• Net income was $0.5 million for the three months ended June 30, 2026, down from $87.1 million in 2025.
• Net loss was $66.0 million for the six months ended June 30, 2026, due to acquisition-related expenses.
• Cash, cash equivalents, and investments totaled $691.6 million as of June 30, 2026.

Evolution Toward Neuroscience

Alkermes has shifted from a technology provider to a developer of its own specialty medicines. The acquisition of LUMRYZ marks a significant expansion into sleep disorders alongside its established mental health treatments.